SCHEMBL21660596

SCHEMBL21660596

CC1(C)C=CC2=C(C=C1)NC(=O)CC2

nearest known ligand 0.37

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22479922 0.82
SCHEMBL25475096 0.72
SCHEMBL21447622 0.68 FKBP5 (0.30) CRBN
SCHEMBL13068886 0.67 GSK3A (0.38)
SCHEMBL21349639 0.66 MEN1 (0.31)
SCHEMBL22694645 0.65
SCHEMBL21447620 0.64 HTR2C (0.32)
SCHEMBL22642201 0.64
SCHEMBL23889389 0.63 GSK3B (0.31)
SCHEMBL23395009 0.63

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023101710-A1 METHODS OF TREATING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS AND ADDITIONAL THERAPEUTIC AGENTS VERU INC. (US) 2023-06-08 WO disclosed
WO-2020028593-A9 A METHOD OF TREATING ER MUTANT EXPRESSING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) Oncternal Therapeutics, Inc. (US) 2021-03-18 WO disclosed
EP-3733170-A1 A METHOD OF TREATING ANDROGEN RECEPTOR (AR) -POSITIVE BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARMS) Oncternal Therapeutics, Inc. (US) 2020-11-04 EP disclosed
WO-2020028593-A1 A METHOD OF TREATING ER MUTANT EXPRESSING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) Oncternal Therapeutics, Inc. (US) 2020-02-06 WO disclosed